Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

CD30/TNFRSF8 Antibody (Ber-H2 + CD30/412), Novus Biologicals™
SDP

Mouse Monoclonal Antibody

Supplier:  Novus Biologicals NBP2445630.1ML

 View more versions of this product

Catalog No. NBP24456301


Only null left
Add to Cart

Description

Description

Ensure accurate, reproducible results in Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

CD30/TNFRSF8 Monoclonal specifically detects CD30/TNFRSF8 in Human samples. It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.
Specifications

Specifications

CD30/TNFRSF8
Monoclonal
0.2mg/mL
Flow Cytometry 5 - 10 ul/million cells in 0.1ml, Immunohistochemistry-Paraffin 1:100-1:200, Immunofluorescence 1:50 - 1:100
P28908
TNFRSF8
Co cell line established from a patient with Hodgkin's disease of T-cell lineage (Ber-H2); human CD30 recombinant protein (CD30/412)
0.1 mL
Apoptosis, Cell Cycle and Replication, Embryonic Stem Cell Markers, Immunology, Stem Cell Markers
943
Human
Supernatant
Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
Ber-H2 + CD30/412
Unconjugated
No buffer with 0.05% Sodium Azide
CD30, CD30 antigen, CD30KI-1, CD30L receptor, cytokine receptor CD30, D1S166EKi-1, Ki-1 antigen, Lymphocyte activation antigen CD30, tumor necrosis factor receptor superfamily member 8, tumor necrosis factor receptor superfamily, member 8
Mouse
Tissue culture supernatant
RUO
Primary
Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkins disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This MAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).
Store at 4C.
IgG
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.

For Research Use Only